Healthcare Professionals


Medical and peer-reviewed support for:

FITC Anti-Rabies Monoclonal Globulin References

  1. The World Health Organization, 1966. Laboratory Techniques in Rabies, Monograph Series No. 23, Second edition.
  2. The World Health Organization, 1966. WHO Expert Committee on Rabies. Technical Report Series No. 312 Fifth edition.
  3. McQueen JL, Lewis AL, and Schneldei NJ, 1960. Rabies Diagnosis by Fluorescent Antibody. Its Evaluation in a Public Health Laboratory. Amer J. Publ. Hlth. 50:1743-1752.
  4. Wiktor TJ, Koprowski H. 1978. Monoclonal Antibodies Against Rabies Virus Produced by Somatic Cell Hybridization: Detection of Antigenic Variants. Proc. Natl. Acad. Sci., U.S.A. 75:3938
  5. Wiktor, T.J., Flamand, A., and Koprowski, H. 1980. Use of Monoclonal Antibodies In Diagnosis of Rabies Virus Infection and Differentiating of Rabies and Rabies-Related Viruses. J. Virol. Methods. 1:1-10.
  6. Letter on file at Centocor from George M. Baer, D.V.M., Centers for Disease Control, Lawrenceville Facility. April 20, 1987.

^ Back to top ^

CA-125II References

  1. van Kamp GJ, Verstraeten RA and Kenemans P.: Discordant serum CA 125 values in commercial immunoassays. Eur. J. Obstet. Gynecol. Reprod. Biol. 49:99-103, 1993.
  2. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC.: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin. Invest. 68:1331-1337, 1981.
  3. O'Brien TJ, Raymond LM, Bannon GA, Ford DH, Hardardottir H, Miller FC, Quirk JG.: New monoclonal antibodies identifying the glycoprotein carrying the CA 125 epitope. Am. J. Obstet. Gynecol. 165(6 pt 1): 1857-1864. 1991.
  4. Kabawat SE, Bast RC Jr, Welch WR, Knapp RC, Colvin RB.: Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of ovarian tumors of surface antigens of ovarian tumors of serous, endometrioid and clear cell types. Am. J. Clin Pathol. 79:98-104,1983.
  5. Bast RC Jr, Klug TL, St. John E, Jenmison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths T, Parker L, Zurawski VR Jr, Knapp RC.: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309:883-887,1933.
  6. Klug TL, Bast RC Jr, Niloff JM, Knapp RC, Zurawski VR Jr.: Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res. 44:1048-1053, 1984.
  7. Kabawat SE, Bast RC Jr, Bhan AK, Welch WR, Knapp RC, Colvin RB: Tissue distribution of a coelomic epithelium related antigen recognized by the monoclonal antibody OC 125. Int. J. Gyn. Path. 2:275-285,1983.
  8. Davis HM, Zurawski VR Jr, Bast RC Jr, Klug TL: Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res, 46:6143-6148, 1986.
  9. Berek JS, Knapp RC, Malkasian GD, Lavin PT, Whitney C, Niloff JM and Bast RC Jr: CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet. Gynecol. 67:685-689, 1986.
  10. Niloff JM, Bast RC Jr, Schaetzl EM, Knapp RC.: Predictive value of CA 125 antigen levels at second-look procedures in ovarian cancer Am. J. Obstet. Gynecol. 151:981-986, 1985.
  11. Atack DB, Nisker JA, Allen HH, Tustanoff ER, Levin L.: CA 125 surveillance and second-look laparotomy in ovarian carcinoma. Am. J. Obstet. Gynecol. 154:287-289, 1986.
  12. Niloff JM, Klug TL, Schaetzl E, Zurawski VR Jr, Knapp RC, Bast RC Jr.: Elevation of serum CA 125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am. J. Ob. Gynecol. 148:1057-1058, 1984.
  13. Ruibal A, Encabo G, Martinez-Miralles E, Murci C, Capdenba BA, Salgado Martinex-Vasquez JM.: CA 125 serum levels in non-malignant pathologies. In Bull. Cancer (Paris), Masson Press 71:145-148, 1984.
  14. Eerdekens MW, Nouwen EJ, Pollet DE, Briers TW and DeBroe ME: Placental alkaline phosphatase and cancer antigen 125 in sera of Patients with benign and malignant diseases. Clin Chem. 31:687-690,1985.
  15. Halila H, Stemnan UH, Seppala M.: Ovarian cancer antigen CA 125 in pelvic inflammatory disease and pregnancy. Cancer 57:1327-1329,1986.
  16. Barbieri RL, Niloff JM, Bast RC Jr, Schaetzl E, Kistmer RW, Knapp RC.: Elevated serum concentrations of CA 125 in patients with advanced endometriosis. Fert. and Steril. 45:630-634, 1986.
  17. Ricolleau G, Chatal JF, Fumoleau P, Kremer M, Douillard JY, Curtet C.: Radiommunomassay of the CA 125 antigen in ovarian carcinomas: advantages compared with CA 19-9 and CEA. Tumor Biol. 5:151-159,1984.
  18. Canney PA, Moore M, Wilkinson PM, James RD.: Ovarian cancer antigen CA 125: a prospective clinical assessment of its role as a tumor marker. Br. J. Cancer 50:765-769, 1984.
  19. Krebs HB, Goplerud DR, Kilpatrick SJ, Myers MB, Hunt A.: Role of CA 125 as tumor marker in ovarian carcinoma. Obstet. Gynecol. 67:473-477, 1986.
  20. Kivinen S, Kuoppala T, Leppilampi M, Vuori J, Kauppila A.: Tumor-associated antigen CA 125 before and during the treatment of ovarian carcinoma. Obstet. Gynecol. 67:468-472, 1986.
  21. Einhorn N, Bast RC Jr, Knapp RC, Tjernberg B, Zurawski VR, Jr.: Preoperartive evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet. Gynecol. 67:414-416, 1986.
  22. Zurawski VR, Broderick SF, Pickens P, Knapp RC, Bast RC Jr.: Serum CA 125 levels in a Group of Non-hospitalized Women: Relevance for the early detection of Ovarian Cancer. Obstet. Gynecol 69:606-611, 1987.
  23. Niloff JM, Knapp RC, Schaetzl E, Reynolds C, Bast RC, Jr.: CA 125 levels in obstetric and gynecologic patients. Obstet. Gynecol. 64:703-707, 1984.
  24. Bast RC Jr, Klug TL, Schaetzl E, Lavin 0, Niloff JM, Greber TF, Zurawski VR, Jr., Knapp RC.: Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and CEA. Am. J. Obstet. Gynecol. 149:553-559, 1984.
  25. Muto MG, Finkler NJ, Kassis AI, Lepisto EM, Knapp RC.: Human antimurine antibody responses in ovarian cancer patients and undergoing radioimmunotherapy with the murine monoclonal antibody OC 125. Gynecol. Oncol. 38:244 248, 1990.
  26. Turpeinen U, Iehtovirta P, Alfthan H, Stenman U.: Interface by human antiidiotypic antibodies not neutralized by mouse IgG but removed by chromatography. Clin. Chem. 36(7):1333-1338, 1990.
  27. Reinsberg J, Heydweillier A, Wagner U, Pfell K, Oehr P, Krebs D.: Evidence for interaction of human anti-idiotype antibodies with the CA 125 determination in a patient after radiommumodetection. Clin. Chem. 36(l):164-167, 1990.
  28. Reinsberg J, Gast B.: Human antiodiotypic antibodies against OC 125 strongly interfere with one-step assays of CA 125 employing OC 125 and M II antibodies. Clin. Chem. 40(6):951-952, 1994.
  29. Kenemans P, van Kamp GJ, Oehr P, Verstraeten RA.: Heterologlous double-determinant immunoradiometric assay Ca 125 II: reliable second-generation immunoassay for determining CA 125 in serum. Clin. Chem. 39:2509-13, 1993.

004-293F 10/99

^ Back to top ^

CA 15-3 References

  1. Cancer Facts & Figures - American Cancer Society 1992.
  2. Parker S, et al.: Cancer Statistics. CA 1996; 65: 5-27.
  3. Chittoor S, Swain S: Adjuvant Therapy in Early Breast Cancer. Am Fam Physician 1991;44:453-462.
  4. Patterson AGH, Lees AW, Hanson J, et al.: Impact of chemotherapy on survival in breast cancer. Lancet 1980;2:312.
  5. Fey K4F, Brunner KW, Sonntag RW- Prognostic factors in metastatic breast cancer. Cancer Clin Trials 1981;4:237-247.
  6. Hilkens, J., et a/.: Monoclonal antibodies against human milkfat globule membranes. Prot Bio/. Fluids 1981;29:813-816.
  7. Hilkens, J., et al.: Monoclonal antibodies against human milkfat globule membranes useful in carcinoma research. Prot. Biol. Fluids 1984;31:1013-1016.
  8. Hilkens, J., et al.: MAM-6 antigen, a new serum marker for breast cancer monitoring. Cancer Research 1986;46:2582-2587.
  9. Hilkens, J., et al.: Monoclonal antibodies against human milkfat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int. J. Cancer 1984;34:197-206.
  10. Kufe, D., et al.: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumor. Hybridoma 1984,3(3):223-232.
  11. Sekine, H., et al.: Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas. J Immunol. 1985;135(5):3610-3615.
  12. Fujino, N., et al.: Clinical evaluation of an immunoradiometric assay for CA 15-3 antigen associated with human mammary carcinomas: Comparison with carcinoembryonic antigen. Jpn. J. Clin. Oncol. 1986;46:335-345.
  13. Colomer, R., et al.: CA 15-3 Early results of a new breast cancer marker. Anticancer Research 1986;6:683-684. 1
  14. Hayes, D.F., et a/.: Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J. Chn. Onco/. 1986;4(10):1542-1550.
  15. Pons-Anticet, D.F.M., et al.: Value of CA 15-3 in the follow-up of breast cancer patients. Brit. J. Cancer 1987;55(5):567-569.

^ Back to top ^

CA 19-9 References

  1. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P: Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genetics 5:957-972, 1979.
  2. Koprowski H, Herlyn M, Steplewski Z, Sears H: Specific antigen in serum of patients with colon carcinoma. Science 212:53-55, 1981.
  3. Magnani J, et al.: The Antigen of Tumor-Specific Monoclonal Antibody is a Ganglioside Containing Sialylated Lacto-N-Fucopentaose II. Federation Proceedings, 41:898, 1982.
  4. Del Villano B, Brennan S, Brock P, Bucher C, Liu V, McClure M, Rake B, Space S, Westrick B, Schoemaker H, Zurawski V Jr: Radioimmunometric Assay for a Monoclonal Antibody-Defined Tumor Marker, CA 19-9. Clin Chem 29:549-552, 1983.
  5. Steinberg W, Gelfand R, Anderson K, Glenn J, Kurtzman SH, Sindelar W, Toskes P: Comparison of the Sensitivity and Specificity of the CA 19-9 and Carcinoembryonic Antigen Assays in Detecting Cancer of the Pancreas. Gastroenterology 90:343-349, 1986.
  6. Ritts R Jr, Del Villano B, Go VLW, Herberman R, Klug T, Zurawski V Jr: Initial Clinical Evaluation of an Immunoradiometeric Assay for CA 19-9 Using the NCI Serum Bank. Int J Cancer 33:339-345, 1984.
  7. Safi F, Beger H, Bittner R, Buchler M, Krautzberger W: CA 19-9 and pancreatic adenocarcinoma. Cancer 57:779, 1986.
  8. NCCLS Guideline EP7-P, entitled "Interference Testing in Clinical Chemistry; Proposed Guideline" August 1986.
  9. NCCLS Guideline EP5-A, entitled "Evaluation of Precision Performance of Clinical Chemistry Devices; Approved Guideline," February 1999.
  10. Del Villano B and Zurawski V Jr: The carbohydrate antigenic determinant 19-9 (CA 19-9): a monoclonal antibody defined tumor marker. Immunodiagnostics - Laboratory and Research Methods in Biology and Medicine, Volume 8. Ed. By J. Hyun and R. Aloisi, Alan R. Liss, New York, pp. 269-282, 1983.

^ Back to top ^